Only one of the many studies that have examined CD34 expression in gliomas found tumoral (as opposed to endothelial) immunoreactivity in lesions classified as WHO grade II or III astrocytomas, oligodendrogliomas or oligoastrocytomas [8]. This evidence concerns the gene CD34 and oligodendroglioma.